MOLECULAR GENETICS OF B CELL LYMPHOMAS: AN UPDATE Michel Trudel, MD, FRCPC Shaikh Khalifa Medical Center.

Slides:



Advertisements
Similar presentations
Kwee Yong, UCL Cancer Institute
Advertisements

Making Sense of Novel Prognostics: NOTCH1, SF3B1 Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute October 24, 2014.
The relative contribution of microenvironmental interactions to the regulation of gene expression programs in multiple myeloma cells Liat Nadav Molecular.
Acquisition of tumour multidrug resistance inevitable in most advanced solid tumours – Failing to cure the majority of advanced solid tumours – Declining.
MYC/BCL2 protein coexpression contributes inferior outcome in DLBCL
Chapter 19 Lecture Concepts of Genetics Tenth Edition Cancer and Regulation of the Cell Cycle.
Wilson WH et al. Proc ASH 2012;Abstract 686.
Cancer-inducing genes - CRGs (cooperation response genes) Paper Presentation Nadine Sündermann.
Proposed WHO Classification of Lymphoid neoplasm
 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an independent.
Cancer Genetics Is Cancer a Genetic Disease? Cancer is not a classic genetic disease, instead, Genetic background (set-up) has a definite role in cancer.
Gene regulation in cancer 11/14/07. Overview The hallmark of cancer is uncontrolled cell proliferation. Oncogenes code for proteins that help to regulate.
1 MicroArray -- Data Analysis Cecilia Hansen & Dirk Repsilber Bioinformatics - 10p, October 2001.
Organization of Genetics Course Molecular Genetics Cytogenetics Transmission Genetics Population Genetics.
Logical Analysis of Diffuse Large B Cell Lymphoma Gabriela Alexe 1, Sorin Alexe 1, David Axelrod 2, Peter Hammer 1, and David Weissmann 3 of RUTCOR(1)
Bioinformatics Ch1. Introduction (continue-2) 阮雪芬 Nov7, 2002 NTUST
Alizadeh et. al. (2000) Stephen Ayers 12/2/01. Clustering “Clustering is finding a natural grouping in a set of data, so that samples within a cluster.
Lymphoma Dr. Raid Jastania Dec By the end of this session you should be able to: –Discuss the basis of the classification of lymphomas –Know the.
Non-Hodgkin Lymphoma Showing Abnormalities of c-myc Including Dual Translocations Involving c-myc and Bcl-2: A Clinicopathologic Study R Jastania, V Kukreti,
Expression of kinase genes in primary hyperparathyroidism; Adenoma versus hyperplastic parathyroid tissue Pinhas P. Schachter1 M.D., Suhail Ayesh2 PhD,
1 April, 2005 Chapter C4.1 and C5.1 DNA Microarrays and Cancer.
 MicroRNAs (miRNAs) are a class of small RNA molecules, about ~21 nucleotide (nt) long.  MicroRNA are small non coding RNAs (ncRNAs) that regulate.
Supervised gene expression data analysis using SVMs and MLPs Giorgio Valentini
1 Robust diagnosis of DLBCL from gene expression data from different laboratories DIMACS - RUTCOR Workshop on Boolean and Pseudo-Boolean Functions in Memory.
E2A – bHLH transcription factor-fusion proteins in Leukemia
Comprehensive Gene Expression Analysis of Prostate Cancer Reveals Distinct Transcriptional Programs Associated With Metastatic Disease Kevin Paiz-Ramirez.
Paola CASTAGNOLI Maria FOTI Microarrays. Applicazioni nella genomica funzionale e nel genotyping DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.
Tumor genetics Minna Thullberg
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.
Challenges and Considerations in Linking Adult and Pediatric Leukemias David G. Poplack M.D. Texas Children’s Cancer Center Baylor College of Medicine.
Identification of network motifs in lung disease Cecily Swinburne Mentor: Carol J. Bult Ph.D. Summer 2007.
Knowledge Discovery in Biomedicine Limsoon Wong Institute for Infocomm Research.
Chapter 7 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.
Clustering of DNA Microarray Data Michael Slifker CIS 526.
Chapter 11 B-Cell Generation, Activation, and Differentiation.
Normal haemopoiesis. ABNORMALITIES IN THE HEMOPOIETIC SYSTEM CAN LEAD TO HEMOGLOBINOPATHIES HEMOPHILIA DEFECTS IN HEMOSTASIS/THROMBOSIS HEMATOLOGICAL.
Finish up array applications Move on to proteomics Protein microarrays.
It is only the beginning: Putting microarrays into context Matthias E. Futschik Institute for Theoretical Biology Humboldt-University, Berlin, Germany.
Background Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. It’s account for about one-third of all.
T-cell/histiocyte-rich large B cell lymphoma Monirath Hav, MD, PhD fellow Pathology Department Ghent University Hospital.
Diagnostically and Prognostically Significant Genetic Alterations in Diffuse Large B-Cell Lymphoma Friederike Kreisel, MD Department of Pathology and Immunology.
Selection of Patient Samples and Genes for Disease Prognosis Limsoon Wong Institute for Infocomm Research Joint work with Jinyan Li & Huiqing Liu.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Apostolos Zaravinos and Constantinos C Deltas Molecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, Department of Biological.
Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.
Eukaryotic Genomes 15 November, 2002 Text Chapter 19.
Non-Hodgkins Lymphoma. risk factor Elderly Men Predisposed: primary and secondary immunodeficiency states – HIV infection – Undergone organ transplantation.
Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.
The genetic basis of antibody structure
Examples of Classifying Expression Data / 7.90 Computational Functional Genomics Spring 2002.
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
Prof. Yechiam Yemini (YY) Computer Science Department Columbia University (c)Copyrights; Yechiam Yemini; Lecture 2: Introduction to Paradigms 2.3.
Case Study: Characterizing Diseased States from Expression/Regulation Data Tuck et al., BMC Bioinformatics, 2006.
Computational Biology and Genomics at Boston College Biology Gabor T. Marth Department of Biology, Boston College
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Gene Expression Signatures, Clinicopathological Features,
R4 고원진 / 백선경 교수님 JOURNAL OF CLINICAL ONCOLOGY Volume 29, Number 14, May 2011 The Gray Zone Between Burkitt’s Lymphoma And Diffuse Large B-Cell Lymphoma.
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Novel Integrative Methods for Gene Discovery Associated.
Evolution-informed Modeling discover biomarkers for precision oncology Li Liu, M.D. August 22, 2016.
by Elaine S. Jaffe, Nancy Lee Harris, Harald Stein, and Peter G
Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw 
GENETIC BIOMARKERS.
5th International Symposium October 22nd – 24th, Varese, Italy
Dept of Biomedical Informatics University of Pittsburgh
Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw 
High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric.
Class Prediction Based on Gene Expression Data Issues in the Design and Analysis of Microarray Experiments Michael D. Radmacher, Ph.D. Biometric Research.
HOXA9 and STAT5 co-occupy similar genomic regions and increase JAK/STAT signaling. HOXA9 and STAT5 co-occupy similar genomic regions and increase JAK/STAT.
Presentation transcript:

MOLECULAR GENETICS OF B CELL LYMPHOMAS: AN UPDATE Michel Trudel, MD, FRCPC Shaikh Khalifa Medical Center

B CELL LYMPHOMAS: MOLECULAR PATHWAYS Pasqualucci & Dalla-Favera, 2002

MICROARRAY EXPRESSION PROFILING: PLATFORMS

MICROARRAY EXPRESSION PROFILING: MOLECULAR INTERACTIONS

MICROARRAY EXPRESSION PROFILING IDENTIFICATION OF:  genes involved in pathogenesis / progression, localization / spread, etc  novel genes / disease categories (“class discovery”)  known cell lineage, differentiation stage, etc (“class prediction”)  genes involved in sensitivity / resistance  risk factors / prognostic groups  novel molecular targets for therapy

FOLLICULAR LYMPHOMA: MORPHOLOGY & PHENOTYPE Grogan, LYMPHOMAS, 1998

FOLLICULAR LYMPHOMA: MOLECULAR GENETICS Ig genesrearranged; IgV genes extensively mutated (intraclonal heterogeneity) KARYOTYPE GENE FREQUENCY FEATURES t(14;18) (q32;q21) BCL2 80% anti-apoptosis sole abnormality in ~ 10% 6q % deletions of ? suppressor genes at q21,q23,q25-27 most common 2 nd abnormality in cells with t(14;18) 3q27 BCL6 transcriptional repressor 40% 5‘ mutations 15% translocations p15, p16 deletions, mutations 17pp53 15% deletions, mutations progression to DLBCL +7, %

FOLLICULAR LYMPHOMA: EXPRESSION PROFILING 6 FL (relapsed; no Rx for prior 6 months) vs. GC B-cells (immunomagnetic bead separation) from 6 tonsils Clontech microarray (588 cDNA’s) microarrayRQ-PCR verification 37 genes   genes   8 Husson et al, Blood, 2002

FOLLICULAR LYMPHOMA: DIFFERENTIALLY EXPRESSED GENES UPREGULATED GENES cell cycle control: CDK10, p120, CDKNIA(p21), CDK2A (p16) transcription factors: PAX5, ID2 (B cell differentiation) cell-cell interaction: TNF, IL-2R , IL-4R  signal transduction: MLK3 DOWNREGULATED GENES cell adhesion / communication: MRP 8/14, CD40, thymosin  10

FOLLICULAR LYMPHOMA : CHROMOSOMAL LOCALIZATION OF DIFFERENTIALLY EXPRESSED GENES GENES INCREASEDLOCUS BCL218q21 CDKNIAC (p21)6p21 TNF6p21 JUN1p32-p31 HSF18q24 XPB2q21 MLK311q13 HSP277q PAX59p13 GENES DECREASED S-100 A 8/9 (MRP 8/14)1q12-q22 PAGA1p34

DIFFUSE LARGE B CELL LYMPHOMA: MORPHOLOGY

DIFFUSE LARGE B CELL LYMPHOMA : MOLECULAR GENETICS Ig genes rearranged; IgV genes mutated KARYOTYPE GENE FREQUENCY FEATURES 3 q 27 BCL6 POZ/zinc finger transcriptional repressor required for - GC formation - Ab affinity maturation - TH 2 -dependent immune response 70-75% mutations ( 5' regulatory sequences ) 35% translocations multiple partners ( 5' region truncated, juxtaposed to heterologous promoters) Dalla-Favera et al, 1996, 2000

BCL 6: PROMISCUOUS TRANSLOCATIONS Gaidano et al, 2000

DIFFUSE LARGE B CELL LYMPHOMA : MOLECULAR GENETICS KARYOTYPE GENE FREQUENCYFEATURES t (14;18) (q32;q21) BCL-225%anti-apoptosis transformed FL unfavorable prognosis 17p p53mutations, deletions transformed FL p15, p16mutations, deletions hypermethylation REL, NF  B2transcription factors 20% amplification REL: extranodal lymphoma

DIFFUSE LARGE B CELL LYMPHOMA: GENE PROFILES Alizadeh et al, Nature, 2000

DIFFUSE LARGE B CELL LYMPHOMA: EXPRESSION PROFILING 2 distinct groups identified by microarray analysis 5-year OS  germinal center B-like 76%  activated peripheral B-like 16% Note: prognostic significance independent of IPI residual clinical variability within each type NF-  B pathway constitutively active in “activated peripheral” type ? therapeutic approach to poor prognosis group Alizadeh et al, Nature, 2000 Davis et al, J Exp Med, 2001

MICROARRAY EXPRESSION PROFILING : ISSUES / PROBLEMS  Quality of tumor banking, RNA retrieved  Type of platform: spotted (cDNA), Affymetrix  Standardization / validation of results  Data analysis / management: - large data sets generated on small sample numbers - different clustering algorithms - bioinformatics capabilities - selection of endpoints  Intercurrent variables: therapies, etc  Discrimination of primary from secondary events, epiphenomena, spurious results (false + / – )  Genomics vs proteomics Experience suggests that diseases will continue to be defined by combination of parameters: clinical, morphologic, phenotypic, genotypic